Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Center for Chronic Lymphocytic Leukemia, part of the Hematologic Oncology (Blood Cancers) Treatment Center at Dana-Farber/Brigham and Women's Cancer Center, promotes a comprehensive approach to the treatment of patients with chronic lymphocytic leukemia (CLL). Our program is one of only a few dedicated CLL centers in the country. Our team of specialists has unique expertise in caring for patients with this kind of cancer, including extensive prognostic testing, tissue banking, and access to a leading stem cell transplantation program if necessary.
We are also a centralized hub for CLL research, and our team of laboratory and clinical-based investigators and physicians offers access to clinical trials of new, promising therapies. We are known for our range of clinical trials, which are available for patients with every stage of the disease, from newly-diagnosed to refractory disease.
Patients may access a comprehensive range of services specialized for CLL treatment, including:
From the time of diagnosis, Dana-Farber offers a personalized CLL risk-assessment, which provides detailed, patient-specific information about an individual's disease and prognosis. Our CLL-focused physicians then work with patients to use this information
in planning and implementing treatment strategies. We offer patients with CLL specialized clinical trials, which give patients the opportunity to receive novel therapies on clinical trials. Our ultimate research goal is to improve current therapies
to benefit all patients.
Jennifer R. Brown, MD, PhD, highlights available frontline therapies for chronic lymphocytic leukemia and factors that impact her preference for treatment.
New Patient Appointments
Matthew Davids, MD, MMSc, on Advances in CLL TreatmentMatthew Davids, MD, MMSc, of Dana-Farber’s Center for Chronic Lymphocytic Leukemia, shares updates on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients.
As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.
We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences.
The Blum Resource Center provides patients and family members with a
comfortable environment to learn more about disease treatment and
This video series and resource toolkit features Dana-Farber nutrition specialist Stacy Kennedy, MPH, RD, CSO, LDN, and explores how diet can help support your health and wellbeing during and after cancer treatment.